Clinical Trials on Neoplasms Staging in Japan

Total 2669 results

Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, China, Czechia, Italy, Portugal, Thailand, Hong Kong, Singapore, Bulgaria, Turkey, Mexico, Argentina and more
AbbVie

Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland and more
Celgene

Completed

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)

Lymphoma | Leukemia, Lymphocytic, Chronic, B-Cell

United States, United Kingdom, Germany, France, Italy, Netherlands, Japan
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Pfizer

Completed

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

Ovarian Cancer

United States, Canada, Australia, France, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Austria, Denmark, Hungary, Singapore, Hong Kong, Belgium, Japan, Ireland, Italy, Netherlands, Czechia, Poland, Switzerland, Russian... and more
Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
Sumitomo Pharma America, Inc.

Recruiting

A Study of Oral TP-3654 in Patients With Myelofibrosis

Myelofibrosis

United States, Belgium, France, Japan, Australia, Italy, United Kingdom
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Belgium, Australia, Czechia, Japan, Brazil, France, United Kingdom, Turkey, Greece, Germany
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

Prostatic Neoplasms

United States, Australia, France, Poland, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Romania, Japan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Hungary, Austria, Sweden, Slovaki... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Gastric Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Si... and more
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
AbbVie

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, France, Japan, Puerto Rico, Spain, Taiwan
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

Urinary Bladder Neoplasms

Taiwan, Korea, Republic of, Austria, Germany, China, United States, Greece, Italy, Argentina, Belgium, Brazil, Russian Federation, Spain, Canada, Czechia, France, Mexico, Japan, Poland, Portugal, Australia, Hungary, Turkey, India, Ukraine
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Eli Lilly and Company

Available

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

Australia, Canada, Egypt, India, Italy, Korea, Republic of, Malaysia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Experimental and Clinical Research Center, a cooperation...

Recruiting

Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve (ACON)

Multiple Sclerosis | Demyelinating Diseases | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Italy, United States, Argentina, Australia, Botswana, Brazil, Colombia, Denmark, France, Germany, India, Israel, Japan, Korea, Republic of, Spain, United Kingdom, Zambia
Prof. Valérie Mc Lin
European Society of Pediatric Gastroenterology, Hepatology and Nutrition; European... and other collaborators

Enrolling by invitation

International Registry of Congenital Portosystemic Shunt (IRCPSS) (IRCPSS)

Congenital Porto-Systemic Shunt (CPSS)

Spain, United Kingdom, Canada, United States, Netherlands, France, Israel, Germany, Australia, Turkey, Switzerland, Japan, Belgium, Greece, Hungary, India, Italy
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer

United States, Germany, Israel, Canada, China, Australia, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Russian Federation, Turkey and more
Immunovant Sciences GmbH

Recruiting

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Poland, Romania, Italy, Georgia, Korea, Republic of, Canada, Japan, Hungary, Spain, Serbia, Germany
argenx

Completed

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Israel, Japan, Australia, Spain, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Portugal, Romania, Spain, Switzerland, Netherlands, P... and more
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Spain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Brazil, Poland, Sweden, Italy
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Acromegaly | Pituitary Gigantism

Japan
Eli Lilly and Company

Active, not recruiting

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Breast Cancer

Canada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT)

Breast Cancer

Spain, China, United States, Australia, Hong Kong, Malaysia, Korea, Republic of, Singapore, Belgium, Japan, India, France, Hungary, Romania, Italy, Bulgaria, Germany, Serbia, United Kingdom, South Africa, Canada, Israel, Taiwan, Switz... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Bristol-Myers Squibb

Completed

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Lung Cancer - Non Small Cell Squamous

Belgium, Brazil, China, Germany, Hong Kong, Japan, Korea, Republic of, Taiwan, Thailand, United States, Spain, Australia, Italy, Netherlands, United Kingdom, Denmark, France, Argentina, Austria, Canada, Chile, Colombia, Czechia, Hungary, Irela... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
Ra Pharmaceuticals, Inc.

Active, not recruiting

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Generalized Myasthenia Gravis

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
Novartis Pharmaceuticals

Recruiting

CINC424A2X01B Rollover Protocol

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host Disease

Korea, Republic of, Italy, Belgium, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)

Prostate Cancer

Romania, United States, Israel, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Singapor... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
Novartis Pharmaceuticals

Completed

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

Breast Cancer

United States, China, Belgium, Canada, France, Italy, Taiwan, United Kingdom, Hungary, Australia, Spain, Germany, Singapore, Austria, Japan, Israel, Russian Federation, Korea, Republic of, Thailand, Slovakia, South Africa, Switzer... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Multiple Myeloma

Canada, United States, Israel, Czechia, Turkey, Germany, United Kingdom, Netherlands, Japan, France, Poland, Spain, Brazil
AbbVie

Terminated

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU)

Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lit... and more
AbbVie

Completed

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)

Small Cell Lung Cancer

United States, Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Poland, Portugal, Romania, Russian... and more
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

Non-Small Cell Lung Cancer

United States, Italy, Poland, Spain, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Japan, Korea, Republic of, Lebanon, Mexico, Netherlands and more
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network for Gynaecological Oncological...

Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Endometrial Neoplasms

United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Russian Federation, Spain, Sweden, Taiwan, T... and more
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

Bladder Cancer

Canada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, Bulgaria, Czechia, Hu... and more

Clinical Trials on Neoplasms Staging in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations